Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer
- 1 August 2006
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 34 (1) , 36-44
- https://doi.org/10.1007/s00259-006-0186-3
Abstract
To evaluate low dose non-enhanced CT and standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning of non-small cell lung cancer (NSCLC). Retrospective analysis was performed of 50 consecutive patients with proven NSCLC who had been referred for primary staging (n=41) or restaging (n=9). All patients underwent a multi-phase PET/CT consisting of a low dose non-enhanced attenuation scan and an arterial and portal-venous contrast-enhanced CT scan followed by whole-body PET. Fused datasets of non-enhanced and contrast-enhanced PET/CT were compared per patient by using the TNM staging system, and per lesion regarding localisation, characterisation and delineation of tumour lesions. The staging results were validated either by histopathology or by clinical–radiological follow-up for ≥6 months. In 47/50 patients, the results of T staging did not differ between the two PET/CT protocols. Three patients could only be correctly classified as having T4 tumours after contrast application. Regarding N staging, both protocols yielded the same results. In M staging, there was only one patient with an improvement of the results as a result of contrast application. The lesion-based analysis of 92 sites showed no difference in the accuracy of lesion localisation and only one revision of lesion characterisation by contrast-enhanced PET/CT. The assessment of tumour delineation was altered by contrast application in 58/92 sites (p<0.0001). In 10/50 patients, contrast-enhanced PET/CT detected additional clinically important findings. In patients with advanced NSCLC, contrast-enhanced CT as part of the PET/CT protocol more accurately assessed the TNM stage in 8% of patients compared with non-contrast PET/CT. However, for planning of 3D conformal radiotherapy and non-conventional surgery, contrast-enhanced PET/CT protocols are indispensable owing to their superiority in precisely defining the tumour extent.Keywords
This publication has 30 references indexed in Scilit:
- Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volumeEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- CT in PET/CT: essential features of interpretation.2005
- The Impact of Positron Emission Tomography on Clinical Decision Making in a University-Based Multidisciplinary Lung Cancer PracticeChest, 2005
- PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT.2005
- How much intravenous contrast is needed in FDG-PET/CT?Nuklearmedizin-Nuclear Medicine, 2005
- Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed TomographyNew England Journal of Medicine, 2003
- Special Treatment Issues*Chest, 2003
- Comparative Efficacy of Positron Emission Tomography With Fluorodeoxyglucose in Evaluation of Small (3 cm) Lymph Node LesionsChest, 2000
- Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.Journal of Clinical Oncology, 1998